Risk factor
Strong & resilient to price shocks
Profitability factor
Strong growth
About
Medartis Holding AG is a global medical technology firm that develops, manufactures, and distributes implantable solutions. These advanced medical devices are utilized worldwide for the surgical stabilization of bone fractures in both the upper and lower extremities, in addition to addressing complex cranio-maxillofacial surgical needs. The company's portfolio features osteosynthesis instruments, marketed under the APTUS and MODUS brands, specifically designed for various body regions including the hand, wrist, elbow, shoulder, foot, and ankle, as well as for facial and skull procedures involving the mandible, midface, orthognathic structures, and cranium. Medartis serves a diverse clientele comprising surgeons, hospitals, medical centers, and group purchasing organizations. The company, founded in 1997, is headquartered in Basel, Switzerland.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA
Target Price
The average target price of MED.SW is 111 and suggests 34.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc